Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Will IVUS Ever Take Off in Peripheral Vascular Interventions?

News Conference News ISET 2024

Will IVUS Ever Take Off in Peripheral Vascular Interventions?

January 31, 2024

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

Advent of Outpatient Endovascular Care Part of a ‘Sea Change’ in Medicine

News Conference News ISET 2023

Advent of Outpatient Endovascular Care Part of a ‘Sea Change’ in Medicine

January 26, 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

January 20, 2023

As Outpatient Facilities Proliferate, So Too Does Scrutiny

News Conference News ISET 2023

As Outpatient Facilities Proliferate, So Too Does Scrutiny

January 17, 2023

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

News Conference News SCAI 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

May 23, 2022

SAFE-PAD Provides More Long-term Safety Data for Paclitaxel

News Conference News SCAI 2022

SAFE-PAD Provides More Long-term Safety Data for Paclitaxel

May 22, 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

News Conference News ACC 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

April 04, 2022

Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms

News Conference News VIVA 2021

Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms

October 07, 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

News Conference News ACC 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

May 21, 2021

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

News Conference News LINC 2020

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

February 06, 2020

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

News Conference News LINC 2020

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

January 31, 2020

Leaving the Hospital Nest? OBL Advice From Those Who’ve Done It

News Conference News ISET 2020

Leaving the Hospital Nest? OBL Advice From Those Who’ve Done It

January 28, 2020

News Conference News VEITH 2019

Endovascular Office-Based Labs: Balancing Upsides Against Potential for Abuse

November 28, 2019

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

News Conference News VIVA 2019

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

November 13, 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

News Conference News SCAI 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Yael L. Maxwell

May 21, 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

News Conference News CRT 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Yael L. Maxwell

March 14, 2019

PVI in Symptomatic Lower-Extremity PAD Offers Multiple Benefits, Even 2.5 Years Later

News Conference News ISET 2019

PVI in Symptomatic Lower-Extremity PAD Offers Multiple Benefits, Even 2.5 Years Later

February 07, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.